×

Thank you for your registration, kindly check your email for an update.

Help us understanding your current clinical practice in the management of CKD patients by answering 3 questions:

 

Submit
 
Raising the bar in chronic kidney disease management
Dr Anita Sharma

Dr Anita Sharma

Read More

Prof. David Cherney

Prof David Cherney

Read More

Time (SGT) Topic Speaker
6:00 PM Faculty introductions and scientific agenda Dr Anita Sharma
6:10 PM Checkpoint #1: Evidence and practice interactive session (Slido) Dr Anita Sharma
6:20 PM Your role in early screening diagnosis and treatment in CKD Dr Anita Sharma
6:35 PM Checkpoint #2: Evidence and practice interactive session (Slido) Dr Anita Sharma
6:45 PM Cardio renal benefits of empagliflozin in EMPA-KIDNEY: The final piece of the puzzle Prof David Cherney
7:05 PM Case discussion and Q & A
Early stage CKD patient with a higher eGFR
Dr Anita Sharma
Prof David Cherney
7:30 PM 5 key takeaways and close Dr Anita Sharma

Join Webinar

The Webinar ID: 998 3535 1670

 

 

8th September 2023, Friday

18:00 - 19:30 (SGT)

 

 

Register

For healthcare professionals only. This webinar is for educational purposes only with the intent to communicate the EMPA-KIDNEY trial results. Empagliflozin is not indicated for the treatment of patients with chronic kidney disease in the Philippines. Please refer to the local approved product information for the current indication. Date: August 2023. RIN No: SC-PH-04498

×
Dr Anita Sharma

Dr Anita Sharma

University of Queensland, Australia

  • Practice Principal at Platinum Medical Centre, and Senior Lecturer, Primary Care Unit, University of Queensland
  • Member of Education Committee, Royal College of General Practitioners (RACGP), co-author of the RACGP General Practice Management of type 2 diabetes handbook
  • Special interest in Aviation Medicine and is a Designated Aviation Medical Examiner and a Medical Review Officer for Civil Aviation Authority of Australia
  • Professional interests include education of GPs registrars, medical students and fellow GPs and development of education modules in type 2 diabetes, CKD, heart failure, atrial fibrillation, diabetes, osteoporosis, obesity, anaemia, and medico-legal matters
 
×
Prof Carol Pollock

Prof David Cherney

University of Toronto, Canada

  • Professor of Medicine: Division of Nephrology University of Toronto Ontario Canada
  • Senior Scientist, Nephrology, University Health Network, Faculty of Medicine, Toronto General Hospital Research Institute, Ontario, Canada
  • Director Renal Physiology Laboratory, a clinician scientist, and a physician in the Division of Nephrology at the Toronto General Hospital
  • Member Canadian Society of Nephrology, American Society of Nephrology, Canadian Medical, Ontario Medical Association and Royal College of Physicians and Surgeons Canada
  • The American Society of Nephrology Distinguished Researcher Award June 2019
  • Research interest focuses on the relationship of T1D and renal hemodynamic function, the renin angiotensin aldosterone system, uric acid, urinary biomarkers and glucose lowering therapies
 
Before You Go...
Tell us why you decided not to register to help us improve